Class / Patent application number | Description | Number of patent applications / Date published |
514130100 | Vasoactive intestinal peptide (VIP) or derivative | 8 |
20110178017 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES - The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP. | 07-21-2011 |
20110218149 | COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISORDERS - The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions. | 09-08-2011 |
20130338072 | METHODS FOR TREATING ORGANS - The present invention relates to methods of preventing or reducing the risk of acute and chronic rejection of transplanted organs. The invention relates to the administration of T3, VIP, and T3/VIP nanoparticles to a donor organ in order to prevent or reduce the risk of rejection, e.g. acute or chronic rejection. | 12-19-2013 |
20140080758 | TREATMENT OF KIDNEY DISORDERS WITH VIP FRAGMENTS - The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions. | 03-20-2014 |
20140142039 | Vasoactive lntestinal Peptide Release From Microparticles - Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group. | 05-22-2014 |
20140171371 | Compositions And Methods For The Diagnosis of Schizophrenia - The present disclosure relates to compositions and methods for the diagnosis of schizophrenia. In particular, the instant disclosure is directed to identification of novel copy number variants of sequences associated with the VIPR2 gene, including certain micro-duplications and triplications, and correlation of these copy number variants with schizophrenia. | 06-19-2014 |
20140235541 | COMPOSITIONS AND METHODS FOR TREATMENT OF AORTIC FIBROSIS - The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of aortic fibrosis and other associated conditions. | 08-21-2014 |
20140315811 | OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) WHICH RESTORE THE NORMAL VISUAL FUNCTION IN EARLY GLAUCOMA - The present invention relates to ophthalmic preparations in the form of eyedrops based on PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) which restore the normal visual function in retinal dystrophy/retinopathy and optic neuropathy, with special reference to glaucoma. | 10-23-2014 |